Illumina directors up for re-election to one-year terms include prominent leaders in healthcare such as former FDA Commissioner Scott Gottlieb and longtime Intuitive Surgical CEO Gary Guthart.
Illumina backs its board in proxy fight with Icahn Read More »
The problems keep mounting for Philips, as recently repaired respirators now need to be fixed in a recall the FDA has labeled a Class I event. The devices may supply the wrong amount of air, or no air at all.
Altamira Therapeutics today reported highlights from a peer reviewed article showing efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver.
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
HuidaGene Therapeutics (辉大基因; HuidaGene), a global clinical-stage biotechnology company focused on developing genomic medicine, today announced the selection of Drs. Haiyan Jiang and Alvin Luk as the new members of the Scientific Advisory Board (SAB).
HuidaGene Appoints New Members to the Scientific Advisory Board Read More »
PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.
PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors Read More »
The decision imperils access to the drug more than two decades after its U.S. approval, and could carry consequences for the FDA’s authority over prescription medicines.
Federal judge invalidates FDA approval of abortion pill Read More »
The maker of subscription apps for insomnia and substance abuse began exploring strategic alternatives earlier this month, and is still seeking a sale.
Pear Therapeutics files for Chapter 11 bankruptcy Read More »
Babson Diagnostics today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice
Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D. Read More »
AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.
AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica Read More »
